25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Heidelberg Pharma AG
Buy, Hold or Sell?

Let's analyze Heidelberg Pharma AG together

I guess you are interested in Heidelberg Pharma AG. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Heidelberg Pharma AG. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Heidelberg Pharma AG

I send you an email if I find something interesting about Heidelberg Pharma AG.

1. Quick Overview

1.1. Quick analysis of Heidelberg Pharma AG (30 sec.)










1.2. What can you expect buying and holding a share of Heidelberg Pharma AG? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€0.88
Expected worth in 1 year
€0.67
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
€-0.21
Return On Investment
-8.8%

For what price can you sell your share?

Current Price per Share
€2.37
Expected price per share
€2.31 - €2.54
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Heidelberg Pharma AG (5 min.)




Live pricePrice per Share (EOD)
€2.37
Intrinsic Value Per Share
€-4.78 - €-1.76
Total Value Per Share
€-3.89 - €-0.88

2.2. Growth of Heidelberg Pharma AG (5 min.)




Is Heidelberg Pharma AG growing?

Current yearPrevious yearGrowGrow %
How rich?$45.6m$47.5m$4.2m8.3%

How much money is Heidelberg Pharma AG making?

Current yearPrevious yearGrowGrow %
Making money-$3.6m-$7.4m$3.8m107.1%
Net Profit Margin-159.8%-268.6%--

How much money comes from the company's main activities?

2.3. Financial Health of Heidelberg Pharma AG (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#462 / 967

Most Revenue
#426 / 967

Most Profit
#383 / 967

Most Efficient
#518 / 967
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Heidelberg Pharma AG?

Welcome investor! Heidelberg Pharma AG's management wants to use your money to grow the business. In return you get a share of Heidelberg Pharma AG.

First you should know what it really means to hold a share of Heidelberg Pharma AG. And how you can make/lose money.

Speculation

The Price per Share of Heidelberg Pharma AG is €2.37. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Heidelberg Pharma AG.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Heidelberg Pharma AG, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €0.88. Based on the TTM, the Book Value Change Per Share is €-0.05 per quarter. Based on the YOY, the Book Value Change Per Share is €0.28 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Heidelberg Pharma AG.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.10-4.2%-0.08-3.3%-0.01-0.3%-0.09-3.7%-0.07-2.9%
Usd Book Value Change Per Share-0.09-4.0%-0.06-2.4%0.3113.2%0.021.0%0.020.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.09-4.0%-0.06-2.4%0.3113.2%0.021.0%0.020.8%
Usd Price Per Share3.20-3.37-5.54-5.04-3.95-
Price to Earnings Ratio-8.07-83.31-360.46-80.19-32.42-
Price-to-Total Gains Ratio-34.09-35.59--193.96--61.44--45.41-
Price to Book Ratio3.27-3.04--30.90--257.77--124.60-
Price-to-Total Gains Ratio-34.09-35.59--193.96--61.44--45.41-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.625723
Number of shares380
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.060.02
Usd Total Gains Per Share-0.060.02
Gains per Quarter (380 shares)-21.978.85
Gains per Year (380 shares)-87.8735.38
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-88-9803525
20-176-18607160
30-264-274010695
40-351-3620142130
50-439-4500177165
60-527-5380212200
70-615-6260248235
80-703-7140283270
90-791-8020318305
100-879-8900354340

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%4.08.00.033.3%4.016.00.020.0%5.035.00.012.5%5.057.00.08.1%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%4.016.00.020.0%10.030.00.025.0%16.043.03.025.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.062.00.0%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%4.016.00.020.0%10.030.00.025.0%16.043.03.025.8%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Heidelberg Pharma AG compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.085-0.052-38%0.281-130%0.021-503%0.016-617%
Book Value Per Share--0.8831.004-12%0.941-6%0.525+68%0.449+97%
Current Ratio--6.1293.730+64%2.481+147%1.968+211%2.268+170%
Debt To Asset Ratio--0.4280.326+31%0.548-22%0.507-16%0.361+19%
Debt To Equity Ratio--0.7490.496+51%0.370+102%0.547+37%0.427+75%
Dividend Per Share----0%-0%-0%-0%
Eps---0.089-0.070-22%-0.006-93%-0.078-12%-0.061-31%
Free Cash Flow Per Share---0.133-0.175+31%-0.158+19%-0.114-15%-0.077-42%
Free Cash Flow To Equity Per Share--0.214-0.116+154%0.239-11%0.030+617%0.020+949%
Gross Profit Margin--1.052-1.626+255%1.0550%0.501+110%0.767+37%
Intrinsic Value_10Y_max---1.762--------
Intrinsic Value_10Y_min---4.778--------
Intrinsic Value_1Y_max---0.291--------
Intrinsic Value_1Y_min---0.496--------
Intrinsic Value_3Y_max---0.786--------
Intrinsic Value_3Y_min---1.484--------
Intrinsic Value_5Y_max---1.177--------
Intrinsic Value_5Y_min---2.458--------
Market Cap110453850.000-22%134688450.000141795712.500-5%372934242.745-64%240104506.049-44%180339432.412-25%
Net Profit Margin---1.496-1.598+7%-2.686+79%-5.369+259%-4.718+215%
Operating Margin---2.076-1.833-12%-2.568+24%-5.310+156%-4.780+130%
Operating Ratio--3.0763.659-16%3.768-18%6.532-53%6.082-49%
Pb Ratio2.683-22%3.2723.043+8%-30.903+1044%-257.773+7978%-124.597+3908%
Pe Ratio-6.620+18%-8.07383.311-110%360.463-102%80.195-110%32.418-125%
Price Per Share2.370-22%2.8903.043-5%5.000-42%4.552-37%3.569-19%
Price To Free Cash Flow Ratio-4.441+18%-5.415-4.484-17%-10.874+101%-11.857+119%-19.229+255%
Price To Total Gains Ratio-27.955+18%-34.08935.587-196%-193.964+469%-61.441+80%-45.412+33%
Quick Ratio--4.8462.969+63%2.258+115%1.690+187%2.082+133%
Return On Assets---0.058-0.048-17%-0.104+79%-0.171+194%-0.138+138%
Return On Equity---0.101-0.073-28%-0.098-4%-0.236+133%-0.191+88%
Total Gains Per Share---0.085-0.052-38%0.281-130%0.021-503%0.016-617%
Usd Book Value--45604355.86051823239.251-12%47536240.697-4%26898684.102+70%23100515.485+97%
Usd Book Value Change Per Share---0.094-0.058-38%0.312-130%0.023-503%0.018-617%
Usd Book Value Per Share--0.9791.112-12%1.042-6%0.582+68%0.498+97%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.099-0.078-22%-0.007-93%-0.087-12%-0.068-31%
Usd Free Cash Flow---6889096.140-9054717.410+31%-9787994.320+42%-6184163.910-10%-4156001.178-40%
Usd Free Cash Flow Per Share---0.148-0.194+31%-0.176+19%-0.126-15%-0.086-42%
Usd Free Cash Flow To Equity Per Share--0.237-0.128+154%0.265-11%0.033+617%0.023+949%
Usd Market Cap122371820.415-22%149221333.755157095469.879-5%413173847.537-64%266011782.252-44%199798057.169-25%
Usd Price Per Share2.626-22%3.2023.371-5%5.540-42%5.043-37%3.954-19%
Usd Profit---4621171.661-3617406.506-22%-7491893.451+62%-5495350.517+19%-3889443.097-16%
Usd Revenue--3088711.0862637434.334+17%3038654.779+2%2560503.974+21%1706043.328+81%
Usd Total Gains Per Share---0.094-0.058-38%0.312-130%0.023-503%0.018-617%
 EOD+3 -5MRQTTM+14 -20YOY+15 -195Y+19 -1510Y+17 -17

3.3 Fundamental Score

Let's check the fundamental score of Heidelberg Pharma AG based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-6.620
Price to Book Ratio (EOD)Between0-12.683
Net Profit Margin (MRQ)Greater than0-1.496
Operating Margin (MRQ)Greater than0-2.076
Quick Ratio (MRQ)Greater than14.846
Current Ratio (MRQ)Greater than16.129
Debt to Asset Ratio (MRQ)Less than10.428
Debt to Equity Ratio (MRQ)Less than10.749
Return on Equity (MRQ)Greater than0.15-0.101
Return on Assets (MRQ)Greater than0.05-0.058
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Heidelberg Pharma AG based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5032.756
Ma 20Greater thanMa 502.464
Ma 50Greater thanMa 1002.531
Ma 100Greater thanMa 2002.694
OpenGreater thanClose2.400
Total1/5 (20.0%)

4. In-depth Analysis

4.1 About Heidelberg Pharma AG

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors. It is also developing TLX250-CDx, a diagnostic antibody for diagnosing renal cancer that is in Phase III trials; and triple-negative breast cancer. In addition, the company develops TLX250 (girentuximab), a diagnostic antibody, which is in Phase II study for patients with advanced clear cell renal cell carcinoma; RHB-107, an oral serine protease inhibitor that is in Phase II study to treat COVID-19. It has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.

Fundamental data was last updated by Penke on 2024-09-10 21:36:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Heidelberg Pharma AG earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Heidelberg Pharma AG to the Biotechnology industry mean.
  • A Net Profit Margin of -149.6% means that €-1.50 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Heidelberg Pharma AG:

  • The MRQ is -149.6%. The company is making a huge loss. -2
  • The TTM is -159.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-149.6%TTM-159.8%+10.2%
TTM-159.8%YOY-268.6%+108.8%
TTM-159.8%5Y-536.9%+377.1%
5Y-536.9%10Y-471.8%-65.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-149.6%-132.1%-17.5%
TTM-159.8%-212.2%+52.4%
YOY-268.6%-221.9%-46.7%
5Y-536.9%-373.2%-163.7%
10Y-471.8%-490.1%+18.3%
4.3.1.2. Return on Assets

Shows how efficient Heidelberg Pharma AG is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Heidelberg Pharma AG to the Biotechnology industry mean.
  • -5.8% Return on Assets means that Heidelberg Pharma AG generated €-0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Heidelberg Pharma AG:

  • The MRQ is -5.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -4.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-5.8%TTM-4.8%-1.0%
TTM-4.8%YOY-10.4%+5.6%
TTM-4.8%5Y-17.1%+12.2%
5Y-17.1%10Y-13.8%-3.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.8%-11.1%+5.3%
TTM-4.8%-11.7%+6.9%
YOY-10.4%-11.2%+0.8%
5Y-17.1%-12.9%-4.2%
10Y-13.8%-14.4%+0.6%
4.3.1.3. Return on Equity

Shows how efficient Heidelberg Pharma AG is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Heidelberg Pharma AG to the Biotechnology industry mean.
  • -10.1% Return on Equity means Heidelberg Pharma AG generated €-0.10 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Heidelberg Pharma AG:

  • The MRQ is -10.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -7.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.1%TTM-7.3%-2.9%
TTM-7.3%YOY-9.8%+2.5%
TTM-7.3%5Y-23.6%+16.3%
5Y-23.6%10Y-19.1%-4.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.1%-13.6%+3.5%
TTM-7.3%-16.1%+8.8%
YOY-9.8%-13.6%+3.8%
5Y-23.6%-18.9%-4.7%
10Y-19.1%-19.1%+0.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Heidelberg Pharma AG.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Heidelberg Pharma AG is operating .

  • Measures how much profit Heidelberg Pharma AG makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Heidelberg Pharma AG to the Biotechnology industry mean.
  • An Operating Margin of -207.6% means the company generated €-2.08  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Heidelberg Pharma AG:

  • The MRQ is -207.6%. The company is operating very inefficient. -2
  • The TTM is -183.3%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-207.6%TTM-183.3%-24.3%
TTM-183.3%YOY-256.8%+73.5%
TTM-183.3%5Y-531.0%+347.7%
5Y-531.0%10Y-478.0%-53.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-207.6%-277.8%+70.2%
TTM-183.3%-279.2%+95.9%
YOY-256.8%-234.1%-22.7%
5Y-531.0%-388.9%-142.1%
10Y-478.0%-496.6%+18.6%
4.3.2.2. Operating Ratio

Measures how efficient Heidelberg Pharma AG is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 3.08 means that the operating costs are €3.08 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Heidelberg Pharma AG:

  • The MRQ is 3.076. The company is inefficient in keeping operating costs low. -1
  • The TTM is 3.659. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.076TTM3.659-0.583
TTM3.659YOY3.768-0.109
TTM3.6595Y6.532-2.873
5Y6.53210Y6.082+0.450
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.0762.761+0.315
TTM3.6593.321+0.338
YOY3.7683.430+0.338
5Y6.5325.021+1.511
10Y6.0826.570-0.488
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Heidelberg Pharma AG.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Heidelberg Pharma AG is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.13 means the company has €6.13 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Heidelberg Pharma AG:

  • The MRQ is 6.129. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.730. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.129TTM3.730+2.399
TTM3.730YOY2.481+1.249
TTM3.7305Y1.968+1.762
5Y1.96810Y2.268-0.300
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.1293.734+2.395
TTM3.7303.909-0.179
YOY2.4814.740-2.259
5Y1.9685.955-3.987
10Y2.2686.303-4.035
4.4.3.2. Quick Ratio

Measures if Heidelberg Pharma AG is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Heidelberg Pharma AG to the Biotechnology industry mean.
  • A Quick Ratio of 4.85 means the company can pay off €4.85 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Heidelberg Pharma AG:

  • The MRQ is 4.846. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.969. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.846TTM2.969+1.878
TTM2.969YOY2.258+0.710
TTM2.9695Y1.690+1.278
5Y1.69010Y2.082-0.392
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.8463.134+1.712
TTM2.9693.444-0.475
YOY2.2584.693-2.435
5Y1.6905.867-4.177
10Y2.0826.479-4.397
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Heidelberg Pharma AG.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Heidelberg Pharma AG assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Heidelberg Pharma AG to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.43 means that Heidelberg Pharma AG assets are financed with 42.8% credit (debt) and the remaining percentage (100% - 42.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Heidelberg Pharma AG:

  • The MRQ is 0.428. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.326. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.428TTM0.326+0.102
TTM0.326YOY0.548-0.223
TTM0.3265Y0.507-0.181
5Y0.50710Y0.361+0.146
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4280.343+0.085
TTM0.3260.346-0.020
YOY0.5480.306+0.242
5Y0.5070.365+0.142
10Y0.3610.382-0.021
4.5.4.2. Debt to Equity Ratio

Measures if Heidelberg Pharma AG is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Heidelberg Pharma AG to the Biotechnology industry mean.
  • A Debt to Equity ratio of 74.9% means that company has €0.75 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Heidelberg Pharma AG:

  • The MRQ is 0.749. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.496. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.749TTM0.496+0.252
TTM0.496YOY0.370+0.127
TTM0.4965Y0.547-0.051
5Y0.54710Y0.427+0.120
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7490.395+0.354
TTM0.4960.450+0.046
YOY0.3700.372-0.002
5Y0.5470.449+0.098
10Y0.4270.488-0.061
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Heidelberg Pharma AG generates.

  • Above 15 is considered overpriced but always compare Heidelberg Pharma AG to the Biotechnology industry mean.
  • A PE ratio of -8.07 means the investor is paying €-8.07 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Heidelberg Pharma AG:

  • The EOD is -6.620. Based on the earnings, the company is expensive. -2
  • The MRQ is -8.073. Based on the earnings, the company is expensive. -2
  • The TTM is 83.311. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.620MRQ-8.073+1.453
MRQ-8.073TTM83.311-91.384
TTM83.311YOY360.463-277.152
TTM83.3115Y80.195+3.116
5Y80.19510Y32.418+47.777
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.620-2.335-4.285
MRQ-8.073-2.413-5.660
TTM83.311-2.978+86.289
YOY360.463-3.462+363.925
5Y80.195-6.080+86.275
10Y32.418-6.254+38.672
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Heidelberg Pharma AG:

  • The EOD is -4.441. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -5.415. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -4.484. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.441MRQ-5.415+0.974
MRQ-5.415TTM-4.484-0.931
TTM-4.484YOY-10.874+6.390
TTM-4.4845Y-11.857+7.373
5Y-11.85710Y-19.229+7.372
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.441-3.054-1.387
MRQ-5.415-3.229-2.186
TTM-4.484-3.575-0.909
YOY-10.874-4.723-6.151
5Y-11.857-8.076-3.781
10Y-19.229-8.636-10.593
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Heidelberg Pharma AG is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.27 means the investor is paying €3.27 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Heidelberg Pharma AG:

  • The EOD is 2.683. Based on the equity, the company is underpriced. +1
  • The MRQ is 3.272. Based on the equity, the company is fair priced.
  • The TTM is 3.043. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.683MRQ3.272-0.589
MRQ3.272TTM3.043+0.229
TTM3.043YOY-30.903+33.946
TTM3.0435Y-257.773+260.816
5Y-257.77310Y-124.597-133.176
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.6831.829+0.854
MRQ3.2721.903+1.369
TTM3.0432.225+0.818
YOY-30.9032.412-33.315
5Y-257.7733.546-261.319
10Y-124.5974.109-128.706
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-05-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets71,974
Total Liabilities30,811
Total Stockholder Equity41,163
 As reported
Total Liabilities 30,811
Total Stockholder Equity+ 41,163
Total Assets = 71,974

Assets

Total Assets71,974
Total Current Assets58,571
Long-term Assets13,403
Total Current Assets
Cash And Cash Equivalents 42,619
Net Receivables 3,692
Inventory 11,727
Other Current Assets 533
Total Current Assets  (as reported)58,571
Total Current Assets  (calculated)58,571
+/-0
Long-term Assets
Property Plant Equipment 3,557
Goodwill 6,111
Intangible Assets 2,758
Long-term Assets Other 977
Long-term Assets  (as reported)13,403
Long-term Assets  (calculated)13,403
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities9,556
Long-term Liabilities21,255
Total Stockholder Equity41,163
Total Current Liabilities
Short-term Debt 114
Accounts payable 4,795
Other Current Liabilities 1,089
Total Current Liabilities  (as reported)9,556
Total Current Liabilities  (calculated)5,997
+/- 3,559
Long-term Liabilities
Capital Lease Obligations 171
Long-term Liabilities Other 0
Long-term Liabilities  (as reported)21,255
Long-term Liabilities  (calculated)171
+/- 21,083
Total Stockholder Equity
Common Stock46,605
Retained Earnings -320,406
Accumulated Other Comprehensive Income 2,022
Other Stockholders Equity 312,942
Total Stockholder Equity (as reported)41,163
Total Stockholder Equity (calculated)41,163
+/-0
Other
Capital Stock46,605
Cash and Short Term Investments 42,619
Common Stock Shares Outstanding 46,605
Current Deferred Revenue3,559
Liabilities and Stockholders Equity 71,974
Net Debt -21,250
Net Invested Capital 41,163
Net Working Capital 49,015
Short Long Term Debt Total 21,368



6.2. Balance Sheets Structured

Currency in EUR. All numbers in thousands.

 Trend2024-05-312024-02-292023-11-302023-08-312023-05-312023-02-282022-11-302022-08-312022-05-312022-02-282021-11-302021-08-312021-05-312021-02-282020-11-302020-08-312020-05-312020-02-292019-11-302019-08-312019-05-312019-02-282018-11-302018-08-312018-05-312018-02-282017-11-302017-08-312017-05-312017-02-282016-11-302016-08-312016-05-312016-02-292015-11-302015-08-312015-05-312015-02-282014-11-302014-08-312014-05-312014-02-282013-11-302013-08-312013-05-312013-02-282012-11-302012-08-312012-05-312012-02-292011-11-302011-08-312011-05-312011-02-282010-11-302010-08-312010-05-312010-02-282009-11-302009-08-312009-05-312009-02-28
> Total Assets 
0
0
0
12,013
14,001
6,747
10,994
5,591
8,270
28,125
24,046
20,814
26,326
22,414
43,174
37,721
32,532
27,983
24,917
22,312
18,969
16,574
16,125
15,030
13,994
17,139
15,427
12,102
13,028
15,948
13,937
15,241
13,304
16,188
15,112
41,490
38,064
36,900
34,881
31,192
28,326
26,968
25,912
22,990
19,026
29,075
25,398
19,609
17,541
15,691
28,547
21,732
20,652
33,937
29,805
100,582
86,476
77,965
74,328
70,353
61,666
71,974
71,97461,66670,35374,32877,96586,476100,58229,80533,93720,65221,73228,54715,69117,54119,60925,39829,07519,02622,99025,91226,96828,32631,19234,88136,90038,06441,49015,11216,18813,30415,24113,93715,94813,02812,10215,42717,13913,99415,03016,12516,57418,96922,31224,91727,98332,53237,72143,17422,41426,32620,81424,04628,1258,2705,59110,9946,74714,00112,013000
   > Total Current Assets 
0
0
0
10,134
12,174
4,792
9,084
3,399
6,134
15,573
11,321
7,997
13,644
9,711
30,503
25,189
20,138
15,697
12,959
9,506
6,240
3,847
3,402
2,910
1,849
5,043
3,426
2,069
3,082
5,834
3,743
4,990
3,134
5,983
4,837
31,209
27,705
25,983
23,992
20,289
17,119
15,701
14,566
11,594
7,343
16,973
13,109
7,521
5,208
3,073
15,859
9,013
8,041
21,439
17,267
87,880
73,673
64,887
61,373
56,634
48,116
58,571
58,57148,11656,63461,37364,88773,67387,88017,26721,4398,0419,01315,8593,0735,2087,52113,10916,9737,34311,59414,56615,70117,11920,28923,99225,98327,70531,2094,8375,9833,1344,9903,7435,8343,0822,0693,4265,0431,8492,9103,4023,8476,2409,50612,95915,69720,13825,18930,5039,71113,6447,99711,32115,5736,1343,3999,0844,79212,17410,134000
       Cash And Cash Equivalents 
0
0
0
3,411
10,659
3,309
7,762
1,943
4,624
13,516
8,073
3,421
7,883
2,920
28,677
23,363
17,675
12,894
9,876
8,920
5,546
2,832
2,821
2,197
1,369
4,101
3,068
1,306
2,305
5,142
3,269
4,574
2,568
5,504
4,491
30,381
27,151
25,535
22,709
19,440
16,069
13,109
12,709
9,884
4,903
15,129
9,226
4,982
2,915
930
13,598
6,141
4,515
18,017
10,523
81,329
65,011
57,379
50,675
43,439
32,650
42,619
42,61932,65043,43950,67557,37965,01181,32910,52318,0174,5156,14113,5989302,9154,9829,22615,1294,9039,88412,70913,10916,06919,44022,70925,53527,15130,3814,4915,5042,5684,5743,2695,1422,3051,3063,0684,1011,3692,1972,8212,8325,5468,9209,87612,89417,67523,36328,6772,9207,8833,4218,07313,5164,6241,9437,7623,30910,6593,411000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10
0
0
0
0
0
0
0
0
0
0
0
-30
0
0
0
0
0
0
000000-3000000000000100000000000000000000000000000000000000000000
       Net Receivables 
0
0
0
6,689
0
0
0
0
258
710
1,967
3,109
4,358
6,429
1,533
270
2,245
2,571
1,685
508
266
964
299
524
183
741
117
485
159
180
61
225
208
336
169
650
108
307
1,237
671
1,001
1,393
747
1,230
501
495
2,613
1,188
1,434
1,302
1,151
1,449
1,140
1,506
1,903
1,452
2,595
1,380
1,060
2,324
3,256
3,692
3,6923,2562,3241,0601,3802,5951,4521,9031,5061,1401,4491,1511,3021,4341,1882,6134955011,2307471,3931,0016711,237307108650169336208225611801594851177411835242999642665081,6852,5712,2452701,5336,4294,3583,1091,96771025800006,689000
       Other Current Assets 
0
0
0
0
1,481
1,449
1,287
1,290
1,108
1,099
1,050
952
884
0
0
1,567
0
0
2,955
0
645
0
553
0
345
0
0
0
466
421
218
0
319
0
0
0
473
0
0
0
0
2,552
1,825
1,473
1,597
1,261
3,575
2,309
1,718
1,545
1,454
2,126
2,249
2,365
2,514
513
808
914
744
383
713
533
5337133837449148085132,5142,3652,2492,1261,4541,5451,7182,3093,5751,2611,5971,4731,8252,552000047300031902184214660003450553064502,955001,567008849521,0501,0991,1081,2901,2871,4491,4810000
   > Long-term Assets 
0
0
0
1,879
1,827
1,955
1,911
2,192
2,137
12,552
12,724
12,818
12,682
12,702
12,671
12,532
12,394
12,285
11,958
12,805
12,729
12,727
12,724
12,120
12,145
12,096
12,001
10,033
9,946
10,114
10,194
10,252
10,170
10,205
10,275
10,281
10,359
10,917
10,889
10,903
11,207
11,267
11,346
11,396
11,683
12,102
12,289
12,088
12,333
12,618
12,688
12,719
12,611
12,498
12,537
12,702
12,803
13,078
12,955
13,719
13,551
13,403
13,40313,55113,71912,95513,07812,80312,70212,53712,49812,61112,71912,68812,61812,33312,08812,28912,10211,68311,39611,34611,26711,20710,90310,88910,91710,35910,28110,27510,20510,17010,25210,19410,1149,94610,03312,00112,09612,14512,12012,72412,72712,72912,80511,95812,28512,39412,53212,67112,70212,68212,81812,72412,5522,1372,1921,9111,9551,8271,879000
       Property Plant Equipment 
0
0
0
424
405
567
552
864
834
1,686
1,947
2,074
2,061
2,135
2,154
2,087
2,011
1,945
1,677
1,345
1,300
1,308
1,255
1,062
1,004
936
905
1,004
951
1,129
1,182
1,278
1,192
1,212
1,290
1,329
1,381
1,741
1,729
1,970
2,231
2,286
2,385
2,457
2,729
3,151
3,314
3,144
3,308
3,564
3,621
3,694
3,577
3,488
3,548
3,747
3,832
4,123
4,012
3,847
3,695
3,557
3,5573,6953,8474,0124,1233,8323,7473,5483,4883,5773,6943,6213,5643,3083,1443,3143,1512,7292,4572,3852,2862,2311,9701,7291,7411,3811,3291,2901,2121,1921,2781,1821,1299511,0049059361,0041,0621,2551,3081,3001,3451,6771,9452,0112,0872,1542,1352,0612,0741,9471,686834864552567405424000
       Goodwill 
0
0
0
0
0
0
0
0
0
8,924
8,924
6,111
6,111
6,111
0
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,111
6,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,1116,11106,1116,1116,1118,9248,924000000000
       Intangible Assets 
0
0
0
1,294
1,261
1,227
1,197
1,166
1,141
1,779
1,690
4,356
4,248
4,194
0
4,107
4,045
4,001
3,933
3,074
3,037
3,007
2,977
2,949
2,928
2,913
2,899
2,869
2,859
2,849
2,869
2,841
2,835
2,831
2,823
2,820
2,815
2,942
2,922
2,801
2,823
2,828
2,808
2,801
2,786
2,783
2,807
2,818
2,869
2,898
2,911
2,901
2,887
2,864
2,843
2,838
2,824
2,809
2,796
2,787
2,770
2,758
2,7582,7702,7872,7962,8092,8242,8382,8432,8642,8872,9012,9112,8982,8692,8182,8072,7832,7862,8012,8082,8282,8232,8012,9222,9422,8152,8202,8232,8312,8352,8412,8692,8492,8592,8692,8992,9132,9282,9492,9773,0073,0373,0743,9334,0014,0454,10704,1944,2484,3561,6901,7791,1411,1661,1971,2271,2611,294000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
45
45
0
0
35
35
35
0
0
0
35
0
0
0
00035000353535004545000000000000000000000000000000000000000000000000
> Total Liabilities 
0
0
0
8,968
7,604
6,605
6,464
6,886
15,483
29,105
27,760
25,337
23,459
22,695
21,724
17,800
14,565
11,543
8,875
7,362
6,884
6,005
2,963
3,154
3,180
3,010
2,938
2,622
2,150
2,253
1,946
5,485
5,481
5,649
7,904
4,466
3,422
4,345
4,872
5,306
5,410
5,390
5,330
6,697
7,127
7,545
6,794
6,730
10,913
15,765
14,799
15,033
21,016
35,513
35,878
33,938
26,311
27,074
22,840
21,013
16,552
30,811
30,81116,55221,01322,84027,07426,31133,93835,87835,51321,01615,03314,79915,76510,9136,7306,7947,5457,1276,6975,3305,3905,4105,3064,8724,3453,4224,4667,9045,6495,4815,4851,9462,2532,1502,6222,9383,0103,1803,1542,9636,0056,8847,3628,87511,54314,56517,80021,72422,69523,45925,33727,76029,10515,4836,8866,4646,6057,6048,968000
   > Total Current Liabilities 
0
0
0
8,351
7,109
6,105
6,082
6,504
15,267
21,705
21,045
20,205
19,671
20,074
18,751
16,739
14,332
11,351
8,754
7,285
6,820
5,992
2,956
3,152
3,180
3,010
2,938
2,616
2,145
2,248
1,941
5,478
5,474
5,642
7,897
4,457
3,414
4,337
4,863
5,306
5,410
5,390
5,330
6,462
6,879
7,351
6,643
6,628
10,833
15,709
14,672
14,935
20,961
27,995
29,401
27,934
21,496
23,475
20,406
19,775
16,483
9,556
9,55616,48319,77520,40623,47521,49627,93429,40127,99520,96114,93514,67215,70910,8336,6286,6437,3516,8796,4625,3305,3905,4105,3064,8634,3373,4144,4577,8975,6425,4745,4781,9412,2482,1452,6162,9383,0103,1803,1522,9565,9926,8207,2858,75411,35114,33216,73918,75120,07419,67120,20521,04521,70515,2676,5046,0826,1057,1098,351000
       Short-term Debt 
0
0
0
0
0
58
58
58
58
138
220
10,800
10,488
10,599
278
2,848
2,710
2,734
2,741
2,728
2,585
2,623
67
77
13
7
1
0
0
0
0
3,748
3,767
886
3,879
0
0
0
0
0
0
0
0
0
94
96
98
101
99
96
94
10,556
89
93
87
15,880
90
111
5,659
5,761
5,168
114
1145,1685,7615,6591119015,88087938910,5569496991019896940000000003,8798863,7673,7480000171377672,6232,5852,7282,7412,7342,7102,84827810,59910,48810,8002201385858585800000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,465
0
4,364
0
15,786
0
10,399
5,548
5,648
0
0
005,6485,54810,399015,78604,364010,465000000000000000000000000000000000000000000000000000
       Accounts payable 
0
0
0
2,099
2,451
1,955
1,930
2,040
1,408
1,953
2,824
1,412
1,502
1,624
1,631
904
493
714
493
191
504
515
171
277
151
296
224
279
333
466
310
132
635
525
661
1,501
637
238
989
405
1,181
954
474
1,012
1,783
1,815
2,053
2,812
2,604
1,555
1,108
903
1,237
2,585
4,606
3,051
1,947
3,482
3,967
7,875
5,073
4,795
4,7955,0737,8753,9673,4821,9473,0514,6062,5851,2379031,1081,5552,6042,8122,0531,8151,7831,0124749541,1814059892386371,5016615256351323104663332792242961512771715155041914937144939041,6311,6241,5021,4122,8241,9531,4082,0401,9301,9552,4512,099000
       Other Current Liabilities 
0
0
0
6,252
4,658
4,092
4,094
4,406
13,801
19,614
18,000
7,993
7,681
7,851
14,225
12,987
11,129
7,903
5,351
0
3,730
2,854
2,718
-1
2,385
2,340
2,396
2,337
1,811
1,782
1,630
0
663
3,823
2,948
2,956
2,777
4,098
3,874
4,900
4,228
4,436
4,856
5,450
3,390
3,603
3,362
3,488
2,625
3,525
2,592
2,985
18,941
19,700
19,736
3,986
14,720
15,148
6,108
1,174
1,215
1,089
1,0891,2151,1746,10815,14814,7203,98619,73619,70018,9412,9852,5923,5252,6253,4883,3623,6033,3905,4504,8564,4364,2284,9003,8744,0982,7772,9562,9483,82366301,6301,7821,8112,3372,3962,3402,385-12,7182,8543,73005,3517,90311,12912,98714,2257,8517,6817,99318,00019,61413,8014,4064,0944,0924,6586,252000
   > Long-term Liabilities 
0
0
0
617
495
500
382
382
215
7,401
6,715
5,132
3,788
2,621
2,973
1,061
233
193
121
77
64
13
7
2
0
0
0
6
5
5
5
7
7
7
7
9
9
9
9
0
0
0
0
235
248
193
151
102
79
57
128
98
55
7,518
6,477
6,003
4,815
3,599
2,435
1,238
70
21,255
21,255701,2382,4353,5994,8156,0036,4777,518559812857791021511932482350000999977775556000271364771211932331,0612,9732,6213,7885,1326,7157,401215382382500495617000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
235
85
55
25
0
0
0
94
23
0
7,466
6,377
0
4,735
0
2,335
0
0
0
0002,33504,73506,3777,466023940002555852350000000000000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
3,045
6,397
142
4,530
-1,295
-7,212
-980
-3,714
-4,523
2,867
-281
21,449
19,921
17,968
16,439
16,043
14,950
12,085
10,569
13,162
11,876
10,813
14,129
12,489
9,480
10,879
13,695
11,991
9,756
7,823
10,539
7,208
37,024
34,641
32,555
30,009
25,886
22,916
21,578
20,582
16,293
11,899
21,530
18,604
12,879
6,628
-74
13,747
6,699
-365
-1,576
-6,073
66,644
60,165
50,891
51,488
49,340
45,114
41,163
41,16345,11449,34051,48850,89160,16566,644-6,073-1,576-3656,69913,747-746,62812,87918,60421,53011,89916,29320,58221,57822,91625,88630,00932,55534,64137,0247,20810,5397,8239,75611,99113,69510,8799,48012,48914,12910,81311,87613,16210,56912,08514,95016,04316,43917,96819,92121,449-2812,867-4,523-3,714-980-7,212-1,2954,5301426,3973,045000
   Common Stock
0
0
0
13,781
15,958
15,958
18,413
18,413
18,413
21,613
21,613
21,613
24,815
24,815
31,276
31,276
31,276
31,276
31,276
31,276
31,276
31,276
7,819
7,819
7,819
9,306
9,306
9,306
10,679
12,928
12,928
12,928
12,928
14,968
14,968
22,453
28,103
28,130
28,130
28,133
28,144
28,156
28,158
28,210
28,210
31,031
31,047
31,062
31,062
31,066
34,173
34,176
34,176
34,176
34,176
46,584
46,584
46,600
46,605
46,605
46,605
46,605
46,60546,60546,60546,60546,60046,58446,58434,17634,17634,17634,17634,17331,06631,06231,06231,04731,03128,21028,21028,15828,15628,14428,13328,13028,13028,10322,45314,96814,96812,92812,92812,92812,92810,6799,3069,3069,3067,8197,8197,81931,27631,27631,27631,27631,27631,27631,27631,27624,81524,81521,61321,61321,61318,41318,41318,41315,95815,95813,781000
   Retained Earnings Total Equity00000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
-1,293
0
0
0
0
0
0
0
-1,878
3,297
3,330
3,349
-2,482
3,407
3,399
3,411
-2,848
3,427
3,439
3,451
-2,748
3,473
3,476
3,508
-3,036
3,572
3,604
3,636
-3,357
3,700
3,912
4,071
-3,705
4,316
4,369
4,693
-4,190
5,080
5,226
5,326
-4,880
5,544
227,503
5,927
6,160
6,343
6,491
6,613
6,714
6,798
6,866
7,337
2,022
2,022
2,022
2,0222,0222,0227,3376,8666,7986,7146,6136,4916,3436,1605,927227,5035,544-4,8805,3265,2265,080-4,1904,6934,3694,316-3,7054,0713,9123,700-3,3573,6363,6043,572-3,0363,5083,4763,473-2,7483,4513,4393,427-2,8483,4113,3993,407-2,4823,3493,3303,297-1,8780000000-1,2930000000
   Capital Surplus 00000000000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
113,368
119,943
119,844
127,443
128,787
127,531
135,230
135,105
134,993
141,735
141,642
158,722
161,042
155,893
155,893
155,893
161,763
155,893
155,893
179,349
188,213
181,949
184,588
184,588
190,782
185,666
187,537
187,537
194,113
187,537
190,474
190,471
223,147
210,472
210,444
210,444
218,348
210,430
210,418
210,416
219,458
210,364
221,881
221,884
232,251
221,897
0
238,052
238,055
238,055
238,055
238,055
304,740
304,740
304,771
304,779
312,454
312,722
312,942
312,942312,722312,454304,779304,771304,740304,740238,055238,055238,055238,055238,0520221,897232,251221,884221,881210,364219,458210,416210,418210,430218,348210,444210,444210,472223,147190,471190,474187,537194,113187,537187,537185,666190,782184,588184,588181,949188,213179,349155,893155,893161,763155,893155,893155,893161,042158,722141,642141,735134,993135,105135,230127,531128,787127,443119,844119,943113,368000



6.3. Balance Sheets

Currency in EUR. All numbers in thousands.